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Summary
Objective: To determine the structure (disease) modifying effect of a glycosaminoglycan polypeptide association complex (GP-C; Rumalon®)
in patients with knee and hip osteoarthritis (OA).
Methods: Double-blind, randomized, placebo-controlled five-year study. Primary assessment criterion was change in radiographic joint
space width between baseline and follow-up at 5 years. Secondary outcome criteria included Lequesne algofunctional index (LAI), pain on
passive motion and consumption of non-steroidal antiinflammatory drugs (NSAIDs). The patients received 10 courses of injections of
placebo or GP-C 2 ml intramuscularly in 5 years (two courses each year). Each course included 15 injections administered twice weekly.
Results: There were 277 patients with knee OA and 117 patients with hip OA. Control and GP-C treated groups were comparable as to sex,
age, duration of disease, body weight, X-ray stage and value of LAI at the baseline. Knee joint space at 5 years decreased 0.37±0.08
(mean±standard deviation) mm for GP-C and 0.42±0.08 mm for placebo groups (P=0.68). Hip joint space at 5 years decreased
0.21±0.08 mm for GP-C and 0.22±0.08 mm for placebo groups (P=0.53). In a subset of patients with hip OA, Kellgren–Lawrence≥2 and
JSW≥1 mm, there was a trend in favor of GPC for lower joint space narrowing in 5 years (P=0.11). In addition, there were no statistical
differences between the treatment groups in LAI, pain on passive motion and consumption of NSAIDs. Side-effects after GP-C (14.5%) were
rare, mild and not more frequent than in the placebo group (15%).
Conclusion: We were not able to demonstrate a structure modifying effect of GP-C in OA of the hip or knee. Radiographic progression of OA
in both knee and hip OA was lower than expected in both study groups. © 2000 OsteoArthritis Research Society International
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Osteoarthritis (OA) is the most common joint disorder. In
population studies, radiographic signs appear in most
people above 65 years of age, and in the population above
75 years, radiographic OA is 80%.1
Present day therapy of OA combines non-pharmacologic
and pharmacologic programs aimed at symptom relief.2
Although there are no medications yet proven to alter the
course of OA, there is considerable current research
directed at structure (disease) modification. These agents
are intended to prevent, retard or reverse the morpho-
logical changes of the cartilage in OA in the studies
in humans.3 These drugs may or may not have an
independent effect on symptoms.4335Rumalon® (Robapharm; Pierre Fabre) is a glycos-
aminoglycan peptide complex (GP-C). It is an extract made
of young bovine cartilage and bone marrow, produced by a
standardized method. One millilitre of GP-C contains
2.5 mg of glycosaminoglycan complex (GAG) of molecu-
lar weight over 100 000 Daltons. The GAG consists
of chondroitin-4-sulfate (64.5%), chondroitin-6-sulphate
(16.5%), chondroitin (9.5%), dermatan-sulfate (3.4%),
hyaluronate (2.1%) and keratan-sulfate (4.0%).
GP-C has been suggested as a disease modifying agent
by in vitro, in vivo and in human studies.
In vitro studies by Bollet5 found increased incorporation
of isotope labeled sulfur into chondrocytes after adding
GP-C to the chondrocyte cell culture. Additional studies
by Adam,6 demonstrated increased incorporation of 3H
labeled proline into collagen after the administration of
GP-C in vitro. Also, GP-C has shown inhibition of hyaluro-
nidase, papain and collagenase activity in vitro.7 GP-C
prevented the catabolic effects of interleukin-1 on chondro-
cytes.8
The disease modifying potential of GP-C was tested in a
rabbit model of OA after medial menisectomy.9 In animals
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lower by gross examination and histologic score. There
were lower levels of neutral metalloproteinases and higher
levels of tissue inhibitor of proteinase (TIMP) in the GP-C
treated than the placebo-treated animals. It was concluded
that prophylactic therapy with GP-C effectively in reduced
the severity of OA in this animal model.
In human studies, 50 patients with knee OA were treated
for 3 years with either ibuprofen or ibuprofen plus two
series of GP-C per year.10 After 2 years of treatment,
the GP-C treated patients reported less night and resting
pain, less pain during walking, shorter periods of morning
stiffness and required less analgesia.
Clinical studies of Rejholec examined GP-C vs placebo
in knee OA (5 years) and hip OA (up to 16 years).11
Radiographic progression was less in the GP-C patients.
For secondary outcomes, the GP-C group had fewer
inflammatory exacerbations, mobility of the signal joint was
better, and there was an improved ability to climb up and
down stairs. Joint replacement surgery was performed in
six of the GP-C group and 17 of the controls.
Additional study seemed appropriate as several of
the clinical trials have been questioned on the basis of
methodological issues. The objective of the present study
was to examine the disease modifying effects of long-term
therapy with GP-C in patients with OA of the hip or knee.Methods
PATIENTS
Consecutive patients seen in the Prague Institute of
Rheumatology with pain in at least one knee and/or hip
were screened for OA by ACR classification criteria that
include the radiograph.12,13 The age of patients was limited
to between 40 and 70 years. Additional inclusion criteria for
the knee were patients with knee pain plus radiological
evidence of joint space narrowing (JSN) in at least one of
the three knee compartments and/or osteophytes and/or
subchondral sclerosis. Additonal inclusion criteria for the
hip were patients with hip pain plus radiological evidence of
JSN in one of the two views and/or osteophytes and/or
subchondral osteosclerosis.
Criteria for exclusion were the following: those with knee
pain due to other causes were to be excluded; generalized
OA (OA in three or more joint areas); severe or ‘end-stage’
OA (JSW<1 mm with severe disability preventing the
patient from attending the outpatient department);
presence of primary inflammatory joint disease; surgery on
knees and hips in the past; coexistent severe disease of
kidneys or liver; administration of steroids for any reason in
the prior 3 months and long-term administration of slow-
acting drugs for OA for the preceding 3 months (e.g.,
intraarticular hyaluronate, oral glucosamine-sulfate, oral
chondroitin-sulfate).PROCEDURE
This was a double-blind, controlled, parallel group,
randomized five-year study involving three clinical centers
with all laboratory examinations and all X-ray images
performed at the Prague Institute of Rheumatology.
Consecutive patients were block randomized into two
groups, with a block size of six. Both GP-C and placebo
were prepared in identical vials. The products were identi-
cal in color, smell and consistency and were labeled withthe randomization code. The placebo contained the diluent
(saline) used in the preparation of the GP-C. Patients
received 15 (twice weekly) intramuscular injections per
course, and two courses of injections per year for 5 years
(i.e. a total of 10 courses) of GP-C or placebo. There was
no cross-over of therapy.
Non-steroidal antiinflammatory drugs (NSAIDs) and anal-
gesics were permitted at the discretion of the investigator.
The type and dose of NSAID was recorded as follows:
(1) no NSAID was consumed in the prior month;
(2) NSAIDs were ingested irregularly (i.e. not every day);
(3) analgesic doses of NSAIDs were ingested daily; or
(4) antiinflammatory doses of NSAIDs were ingested daily.
A numerical system was developed to separate levels 3
and 4 for each of the available NSAIDs (Table I).
During the trial the following were not permitted: intra-
articular or systemic corticosteroids; opiate analgesics;
slow acting agents for OA (defined above). Physical
therapy was permitted and its application monitored.
Patients were examined at baseline and subsequently
every 3 months for 5 years. Study medication was provided
by the coordinating center at 6 month intervals. A daily log
recorded adverse events. Radiographs were obtained
yearly (i.e. six images of the signal joint in 5 years).PRIMARY EFFICACY VARIABLE
The primary outcome measure was change in the radio-
graphic joint space from baseline to final visit at 5 years.
The initial 1989 protocol listed six primary outcome vari-
ables: clinical state, patient questionnaire, joint space width
(JSW), summary score of selected X-ray criteria, need for
surgery and consumption of analgesics. During the trial,
and prior to any data analysis, the protocol was amended to
focus on the single variable above.Table I
Numeric system for estimating the use of analgesic vs anti-
inflammatory doses by regular users of several non-steroidal
antiinflammatory drugs
NSAID Analgesic
dose
Antiinflammatory
dose
Diclofenac ≤75 mg >75 mg
Ibuprofen <1600 mg ≥1600 mg
Indomethacin <75 mg ≥75 mg
Salicylates <2500 mg ≥2500 mg
Tiaprofenic acid ≤300 mg >300 mg
Flurbiprofen ≤150 mg >150 mg
Piroxicam ≤10 mg ≥20 mg
Tolfenamic acid ≤200 mg >200 mg
Ketoprofen ≤150 mg >150 mg
Naproxen ≤500 mg >500 mg
Tolectin <1200 mg ≥1200 mg
Tramadol ≤100 mg ≥150 mg
Lonazolac ca <1200 mg ≥1200 mg
Nabumetone <1000 mg ≥1000 mgSECONDARY EFFICACY VARIABLES
Secondary outcome measures included the Lequesne
algofunctional index (LAI) of knee or hip OA,14 pain on
passive motion of the signal joint, global evaluation and
consumption of NSAIDs. The LAI is a composite index of
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patient at each visit with the assistance of a trained nurse.
Global evaluation of OA was reported at each visit
separately by the patient and the physician using the
following 5-point scale to make comparisons with the
pre-study condition: −2=much worse, −1=worse, 0=no
change, +1=better, +2=much better. Passive motion of the
signal joint was performed by the patient and pain recorded
on a 4-point scale: 0=none, 1=mild, 2=moderate, 3=
severe.RADIOLOGICAL EVALUATION
All joint imaging was performed at the Prague Arthritis
Institute. All radiographs were obtained by one radiological
technician using a single X-ray machine (Siemens, Sire
Graph C, Erlangen). X-rays were obtained yearly.
For the knee, the X-ray cassette film was placed 1.15 m
from the tube. Anterioposterior weight-bearing radiographs
were obtained with the patient’s heels and toes together
and knees fully extended. The X-ray beam was horizontal
and the central beam was fluoroscopically directed at the
center of the joint space at the level of the tibial tubercle.
For subsequent studies, the repositioning of the patient
was guided by the original radiograph, and the same
radiographic techniques were repeated (i.e. kilovolts,
milliamps, milliseconds). No other mechanical guides were
used for repositioning.
For the hip, the X-ray cassette film was located 1.15 m
from the tube. A single anteroposterior weight bearing
pelvic radiograph was obtained with the patient’s toes
together. The X-ray beam was horizontal and the central
beam was directed 5 cm above symphysis pubis (not
fluoroscopically placed). As above, for repeat studies the
repositioning of the patient was guided by the original
radiograph, and the same radiographic techniques (i.e.
kilovolts, milliamps, milliseconds) were used. No other
mechanical guides were used for repositioning.those with an initial Kellgren–Lawrence grade ≥ 2.MEASURING JOINT SPACE WIDTH
Joint space width (JSW) was measured on the antero-
posterior radiograph by the method of Lequesne,15 using a
×10 magnifying lens marked with a 20 mm scale at 0.1 mm
intervals. The site of the tibiofemoral compartment selected
for interpretation was based on the site on the baseline
radiograph at which the joint space was narrowest. If the
JSW was equal in both tibiofemoral compartments, the
narrowest point of the compartment adjacent to the largest
osteophyte was measured. If the JSW were equal and the
osteophytes were equal in size, the medial compartment
was measured at its narrowest point. If there was no
narrowest point of the compartment, the midpoint of the
compartment was measured.16 A drawing pencil was used
to mark the radiograph for the measuring points.
Two readers were trained by a skilled radiologist to read
JSW. Readers reviewed radiographs independently. If the
two JSW readings were within 0.3 mm, the mean of the two
values was recorded as the final reading. If the difference
between the two JSW readings was >0.3 mm, the radio-
graphs were reinterpreted by both readers and if the
readings were then within 0.3 mm the mean was recorded.
If the second reading confirmed a difference of >0.3 mm,
the average of the four readings was recorded.
Measurement of JSW and Kellgren–Lawrence grading
was performed on the baseline and final radiographs at thesame time. Radiographs were blinded as to patient name,
date and chronology of the radiograph. Kellgren Lawrence
grading was estimated by both readers, guided by a
radiographic atlas.
Selection of the signal joint was based on the more
painful hip or knee on passive motion. If pain was equal,
the signal joint was from the side with the more severe
changes on the radiograph. If both symptoms and radio-
graphs were equal, the right side became the signal joint.INTRAOBSERVER AND INTEROBSERVER ERROR
Intraobserver error for each reader was estimated on 10
randomly chosen X-rays, measured six times, spaced over
10 days. For the knee, the intraclass correlation was 0.99
for reader A (coefficient of variation 2.0%) and 0.98 for
reader B (coefficient of variation 3.6%). For the hip, the
intraclass correlation was 0.98 for reader A (coefficient
of variation 5.5%) and 0.97 for reader B (coefficient of
variation 6.2%).
The interobserver error was assessed on all radio-
graphs. For the knee, the interclass correlation was 0.97
(coefficient of variation 6.6%) prior to adjudication and 0.98
(coefficient of variation 5.2%) after adjudication. For the hip,
the interclass correlation was 0.99 (coefficient of variation
4.0%) prior to adjudication and 0.99 (coefficient of variation
3.6%) after adjudication.STATISTICAL EVALUATION
Sample size: based on prior clinical trials, it was esti-
mated that 400 patients would be needed to demonstrate
benefit on the six initial variables; i.e. 200 for hip and 200
for knee (programme N of IDV Gauting/Munich).
Data analysis: based on reduction of JSW from baseline
to completion of the study at 5 years using analysis of
covariance with the last observation carried forward miss-
ing value strategy for intent-to-treat analysis. With a single
outcome variable, no correction of a type I alpha error
(considered equal to 5%) was deemed necessary. Knees
and hips were evaluated separately.
The two sided student’s t-test with nominal value of 5%
was selected as the method for comparison for additional
analyses. For the adjusted treatment effect, a 95% interval
of reliability was established. In addition, a non-parametric
analysis of covariance by ranks was calculated.
Additional analyses included those who completed the
study (per protocol analysis), yearly changes in JSW,
intent-to-treat analysis and completer analysis was per-
formed on those with a JSN of >1 mm at baseline, and
17ResultsKNEE: PATIENT POPULATION
There were 280 patients recruited into the study.
Adequate data was available in 277 for intent-to-treat
analysis because three patients did not have a second
radiograph. The 5-year study was completed by 250
patients (90.3%) (Fig. 1). Reasons for premature with-
drawal were adverse reaction in 15 (5.4%), loss of
follow-up in seven (2.6%), and patient decision in five
(1.8%). There were no demographic differences between
the GP-C and placebo treatment groups (Table II). The
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age BMI 31, average LAI 9, disease duration for 6.2 years,
and an average ISK score of 9. The patients had diverse
radiographic scores, averaging 2.7 for the knee by
Kellgren–Lawrence grading. The mean width of the narrow-
est point of the radiographic joint space was 4.2 mm for the
knee. Pain was mostly moderate.Fig. 1. Flow diagram of the study population.Table II
Patient population
Knee Hip
GP-C
(N=138)
Placebo
(N=139)
GP-C
(N=58)
Placebo
(N=59)
Sex (%) Men 37 (27) 33 (24) 21 (36) 18 (31)
Women 101 (73) 106 (76) 37 (64) 41 (70)
Age (years) (mean±S.D.) Men 59.1±7.4 60.6±8.4 52.6±9.2 57.8±9.4
Women 59.2±7.2 58.6±7.9 57.4±8.1 55.8±8.9
All 59.2±9.7 59.1±8.0 55.6±8.7 56.4±9.0
BMI (kg/m2) (mean±S.D.) Men 30.4±3.2 31.3±3.6 28.8±4.1 29.3±2.7
Women 31.1±2.9 31.7±3.6 30.4±2.9 31.4±4.9
All 30.8±4.2 31.5±3.7 29.9±4.4 30.9±3.1
Duration of disease (months) (mean±S.D.) 73.7±96.1 69.1±59.4 70.7±63.2 87.8±79.7
LAI (Points) (mean±S.D.) 8.9±3.5 9.2±3.4 8.2±3.3 8.5±3.8
Stage Kellgren–Lawrence (%) 0 4 (3) 3 (2) 8 (14) 10 (17)
1 19 (14) 18 (13) 17 (29) 21 (36)
2 20 (19) 20 (14) 6 (10) 8 (14)
3 21 (41) 67 (48) 22 (38) 15 (25)
4 33 (24) 31 (22) 5 (9) 5 (9)
Joint space width (mm) 4.2±1.7 4.1±1.7 3.6±1.2 3.8±1.3
Pain on passive movement (%) None 53 (38) 40 (29) 16 (28) 11 (19)
Moderate 71 (51) 80 (58) 32 (54) 40 (71)
Severe 14 (10) 19 (14) 10 (18) 6 (10)KNEE: JSN
Results of the primary efficacy variable for the knee are
recorded in Table III. There was no difference in the
progression of JSN between the GP-C and placebo groups.
The actual change in Kellgren–Lawrence grade is recorded
in Table IV. There was a trend toward more frequentchanges into higher stages with those on placebo
(P=0.094).
A subset analysis of those with knee OA completing the
study with an initial JSN of ≥1 mm and at least a Kellgren–
Lawrence grade of 2 included 86 from the GP-C group and
95 from the placebo group. The JSW was reduced in GP-
C group from 4.31±0.14 to 3.81±0.18 mm (change
−0.49±0.11 mm) and in placebo group from 4.14±0.14 to
3.64±0.16 mm (change −0.50±0.10 mm) after 5 years
(P=0.97) (Table V).
The changes in JSW from knee OA in yearly intervals are
demonstrated in Table V. There are no differences in
values between the study group in any year. The decrease
of JSW was not linear, but was most rapid in the first year
(−0.32 mm) with a slower progression from the second to
the fifth year. The mean annual rate of JSN was 0.1 mm.
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group ≥ 0.5 mm in the 5 years was 31/88 (36%) in the
GP-C group vs 29/95 (31%) in the placebo group.HIP: PATIENT POPULATION
There were 120 patients recruited with adequate data to
analyse 117 by intend-to-treat analysis because three
patients did not have a second radiograph.
There were no differences in the demographics between
GP-C and placebo treatment groups (Table II). There were
64% women, average age 56 years, average BMI 30,
disease duration 7 years, and average LAI 8.4. The mean
JSW at the narrowest point was 3.7 mm. The study
was completed by 100 patients (85.5%). The reasons for
premature withdrawal were adverse reactions in 15
(12.8%) and patient decision in 2 (1.7%).HIP: JSN
Results of the primary efficacy variable for the hip are
recorded in Table VI. As with the knee, there was no
difference in the progression of JSN between the GP-C and
placebo groups. The change in Kellgren–Lawrence grade
is recorded in Table VII. In those with hip OA, there were no
more frequent changes into higher stages with those on
GP-C than those on placebo (P=0.44).
A subset analysis of those with hip OA completing the
study with an initial JSN of ≥1 mm and at least a Kellgren–
Lawrence grade of 2 included 25 from the GP-C group and
21 from the placebo group. JSW was reduced from
3.29±0.15 to 3.06±0.17 mm (change −0.23±0.14 mm) in
GP-C group and from 3.31±0.27 to 2.73±0.26 in placebo
group (change −0.58±0.16 mm). There was no significant
difference but a trend in favor of GP-C (P=0.11).
The changes in JSW from hip OA in yearly intervals are
demonstrated in Table VIII. There are no differences in
values between the study groups in any year. In contrast to
the knee study groups, the decrease of JSN was most rapid
in the last 3 years. The mean annual JSN was 0.045 mm in
the GP-C group and 0.11 mm in the placebo group.
The number of patients who progressed >0.5 mm in the
5 years was 6/25 (24%) in the GP-C group vs 13/21 (62%)
in the placebo group.Table III
Change in knee joint space between GP-C and placebo groups
Study group Baseline
(mean±S.E.M.)
End point Change
(mean±S.E.M.)
Raw
means±S.E.M.
Adjusted
means±S.E.M.
GP-C 4.23±0.15 3.86±0.16 3.81±0.08 −0.37±0.08
Placebo 4.13±0.14 3.71±0.15 3.76±0.08 −0.42±0.08
Difference 0.10±0.20 0.05±0.11 0.04±0.11
95% CI [−0.30; +0.50] [−0.16; +0.25] [−0.17; +0.25]
P (1) value P=0.63 P=0.66 P=0.68
P (2) value P=0.22 P=0.69 P=0.77
P (1): Difference between GP-C and placebo groups; parametric evaluation (two sided t-test).
P (2): Difference betweeen GP-C and placebo groups; non-parametric evaluation (Wilcoxon test).Table IV
Change in Kellgren–Lawrence stage of the knee recorded at final
visit
Baseline 0 1 2 3 4 Total
GP-C
0 4 4
1 18 1 19
2 20 6 26
3 44 12 56
4 33 33
Total 4 18 21 50 45 138
Statistics Value ASE 95% CI
 0.811 0.041 0.731 0.891
Baseline 0 1 2 3 4 Total
Placebo
0 3 3
1 14 2 1 1 18
2 15 4 1 20
3 2 47 18 67
4 31 31
Total 3 14 19 52 51 139
Statistics Value ASE 95% CI
 0.704 0.049 0.608 0.800
Test for equal  (GP-C) and  (placebo), P=0.094.Table V
Change in knee joint space (mm) in yearly intervals (subset of
patients with Kellgren–Lawrence ≥2 and JSW>1 mm, completers)
GP-C
(N=86)
Placebo
(N=95)
Significance
Baseline 4.31±0.14 4.14±0.14 NS
1 year 3.96±0.15 3.84±0.14 NS
2 years 3.92±0.15 3.76±0.14 NS
3 years 3.86±0.15 3.72±0.14 NS
4 years 3.74±0.16 3.59±0.15 NS
5 years 3.81±0.18 3.64±0.16 NS
 change −0.49 mm −0.50 mm NS
GP-C Rumalon®.
Data are mm±S.E.M.
There are no statistical differences between GP-C and placebo.SECONDARY OUTCOME VARIABLES
The knee LAI index decreased 0.56±0.31 points in the
GP-C group in contrast to a decrease of 1.53±0.32 points
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(P=0.04), the reduction of 0.93 points was not considered
clinically relevant. For the hip, there was no change and no
difference in change in the treatment groups of the LAI
grades after 5 years.
There were no statistical differences between the study
groups from baseline to end of study in changes in pain on
passive motion for either knee OA (P=0.39) or hip OA
(P=0.82).
There are no statistical differences in NSAID consump-
tion between the study groups from baseline to end of study
in knee OA (P=0.62) or hip OA (P=0.73).
ADVERSE EVENTS
Adverse events were uncommon. No serious adverse
events were identified that were attributed to the GP-C.
In general, reactions were mild and subsided quickly
(Table IX). There were 59 (14.8%) cases of adverse events
recorded. There were 29 (14.5%) cases in the GP-C
groups and 30 (15.0%) cases in the placebo groups (NS).
Adverse events leading to withdrawal from the study
occurred in 17 (8.5%) of the GP-C groups and 16 (8.0%;
NS) of the placebo groups.
Adverse reactions leading to withdrawals appeared
mostly in the first 3 years (five in year 1, 13 in year 2, 12 in
year 3) and less in the last 2 years (two in year 4, one in
year 5). There were 13 deaths, evenly distributed between
the treatment groups: malignancy (6), ischemic heart
disease (3), pulmonary emboli (2), motor vehicle accident
(2).Table VI
Change in hip joint space between GP-C and placebo groups
Study group Baseline
(mean±S.E.M.)
End point Change
(mean±S.E.M.)
Raw
(mean±S.E.M.)
Adjusted
(mean±S.E.M.)
GP-C 3.60±0.16 3.39±0.19 3.50±0.08 −0.21±0.08
Placebo 3.80±0.17 3.58±0.20 3.47±0.08 −0.22±0.08
Difference 0.20±0.24 0.03±0.12 0.01±0.12
95% CI [−0.67; +0.66] [−0.20; +0.25] [−0.22; +0.24]
P (1) value P=0.39 P=0.82 P=0.91
P (2) value P=0.37 P=0.72 P=0.53
P (1): Difference between GP-C and placebo groups; parametric evaluation (two sided t-test).
P (2): Difference between GP-C and placebo groups; non-parametric evaluation (Wilcoxon test).Table VII
Change in Kellgren–Lawrence stage of the hip recorded at final
visit
Baseline 0 1 2 3 4 Total
GP-C
0 7 1 8
1 16 1 17
2 5 1 6
3 1 18 3 22
4 5 5
Total 7 18 5 20 8 58
Statistics Value ASE 95% CI
 0.837 0.058 0.724 0.950
Baseline 0 1 2 3 4 Total
Placebo
0 10 10
1 1 20 21
2 1 5 2 8
3 13 2 15
4 5 5
Total 11 21 5 15 7 59
Statistics Value ASE 95% CI
 0.865 0.051 0.765 0.966
Test for equal  (GP-C) and  (placebo) P=0.442.Table VIII
Change in hip joint space (mm) in yearly intervals (subset of
patients with Kellgren–Lawrence ≥1 mm, completers)
GP-C
(N=25)
Placebo
(N=21)
Significance
Baseline 3.29±0.15 3.31±0.27 NS
1 year 3.36±0.13 3.42±0.27 NS
2 years 3.29±0.15 3.25±0.27 NS
3 years 3.28±0.15 3.04±0.28 NS
4 years 3.21±0.17 2.94±0.30 NS
5 years 3.06±0.17 2.73±0.26 NS
 change −0.23 mm −0.52 mm NS (P=0.11)
GP-C Rumalon®.
Data are mm±S.E.M.
There are no statistical differences between GP-C and placebo.Discussion
In a 5-year prospective trial, there was no difference in
progression of JSN between GP-C and placebo treatment
for OA of hip or knee. Similarly, there was no difference
between groups in secondary clinical outcome measures or
in subgroup analyses. Given that patients were selected on
the basis of having symptoms, we also failed to demon-
strate any symptom benefit of GP-C over placebo. We were
not able to confirm the results of prior studies performed
by Catona10 and Rejholec.10 However, there are previous
clinical trials that have demonstrated benefit from
GP-C.10,11 It may be that the effects of the GP-C were
small and the measurements selected for the study were
not sensitive enough to detect a difference between the
placebo and the study drug.
This study was designed and initiated in 1989. More
recent publications have described more exact techniques
Osteoarthritis and Cartilage Vol. 8 No. 5 341for measuring joint space for both hip and knee.16–22
Although the standing position for the knee is still recom-
mended, positioning by fluoroscopy, the semi-flexed pos-
itioning of the knee, correction for magnification, the use of
a foot map and digitization of the radiograph with computer
measurement of joint space are examples of the refinement
of radiographic techniques. In this study positioning was
quite reproducible when the radiographs were compared;
however, small changes might not have been detected for
the reasons above.
Patient selection also has an influence on trial results.
This study included patients with Kellgren–Lawrence stage
I and stage IV; stage I might progress slowly, or not at all;
it is probably not possible to show structure-modifying
changes in those with stage IV disease. Current protocols
for structure modification generally recommend studying
only Kellgren–Lawrence stage II and III disease.19 In this
study, the evaluation of those with Kellgren–Lawrence
stages II and III would probably result in a study with
insufficient power to detect a difference.
There are several studies examining the rate of radio-
graphic JSN.23–26 Results of these studies vary from 0.06
to 0.6 mm/year, a 10-fold difference. More extensive study
is needed as much of the present discrepancy may relate to
the radiographic methods, patient selection and the period
of observation. The results of this study point out the need
for the continuing improvement of our imaging tech-
niques. In this regard, we await the validation of magnetic
resonance imaging,27 as well as that of arthroscopy and
surrogate biochemical markers.28,29
There are presently many agents being examined for
structure modification in OA, such as chondroitin sulfate,30
hyaluronate,31 diacerrhein,32 and glucosamine.33 This
study points out several of the difficulties in studyingpotential structure modifying agents. More recent studies
are using refined radiographic techniques, but are studying
the intervention for shorter periods of time, because it
seems that much of the progression often occurs in the
earlier years of a trial. Also, this study suggests that
progression of disease in the non-treatment group may
be slower than one would anticipate from the exist-
ing literature. Investigators need to be aware, and plan
accordingly.
The lack of effect in this study raises concern that JSN
may not be the ideal measure for disease progression in
OA. An alternative is to use an atlas of standard images.16
Although not as quantitative as the above techniques, the
atlases examine the entire joint and not just the thickness of
the articular cartilage.
In summary, there was a slow progression of JSN in this
study of OA of the hip and knee over a 5-year period in a
cohort of 400 patients. In this setting, GP-C failed to
demonstrate structure modification.Acknowledgments
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Adverse events
GP-C
(N)
Placebo
(N)
Pain at injection site 5 19
Skin 8 10
Exanthema 2 2
Skin rash, eruption, rash 3 3
Erythema 2 0
Pruritus 1 4
Edema 0 1
Cardiovascular diseases 4 5
Acute myocardial infarction 2 1
Ischemic heart disease 1 2
Pulmonary embolus 1 1
Congestive heart failure 0 1
Cancer 3* 3+
Surgery 6 3
Knee replacement 2 0
Hip replacement 4 3
Gastro-intestinal system 0 2
Musculo-skeletal system 5 7
Rheumatoid arthritis 1 3
Pain of joint and muscle 4 4
Miscellaneous 7 3
Patients 29 (14.5%) 30 (15%)
Adverse events 38 (19%) 52 (26%)
Drop-out 17 (8.5%) 16 (8%)
Death 7 (3.5%) 6 (3%)
*Colon, prostate, leukemia.
+Colon, pancreas, lung.References
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